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Cutaneous leishmaniasis is a common parasitic disease that is endemic in some parts of Iran. The drugs of
choice used for leishmaniasis therapy are associated with a risk of recurrence and serious adverse effects.
Therefore, ﬁnding a safe and effective treatment is of great importance. In the present study, the effect of
aloe-emodin on the growth of Leishmania major amastigotes was evaluated under in vitro conditions. In
addition, the efﬁcacy of a topical of aloe-emodin ointment was investigated in BALB/c mice with cuta-
neous leishmanial ulcers. Different concentrations (40 mg/mL, 80 mg/mL, 120 mg/mL, and 160 mg/mL) of
aloe-emodin were tested on Leishmania amastigotes twice: 24 hours and 48 hours. The induced
apoptosis and necrotic effects of two concentrations (40 mg/mL and 120 mg/mL) of aloe-emodin on
promastigotes were investigated by ﬂow cytometry. Under the in vivo condition, aloe-emodin ointment
efﬁcacy was evaluated at two concentrations (i.e., 0.1% and 1%). Serum indicator factors of the test and
control groups were tested to evaluate the toxic effects of this compound on the liver and kidney. Results
showed that aloe-emodin inhibited the growth of Leishmania amastigotes and induced apoptosis in
promastigotes. Topical application of aloe-emodin ointment likewise reduced the ulcer size. No signiﬁ-
cant differences in biochemical analysis were observed between the control and treated groups. In
conclusion, aloe-emodin showed antileishmanial effects under in vitro and in vivo conditions and may be
used in clinical trials.
Copyright © 2014, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Leishmaniasis is a vector-born disease caused by protozoan
parasites of the Leishmania genus and transmitted by the phle-
botomine sandﬂy.1 The disease is normally localized to the skin and
infects dermal macrophages, although metastasis to mucosal tissue
and bone marrow can occur.2 Three forms of the disease are cuta-
neous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and
visceral leishmaniasis. In CL, manifestations develop from a small
nodule to ulcerative wounds.3 Cutaneous leishmaniasis is endemic
in 98 countries and ﬁve continents.4 The ﬁve most affected coun-
tries are Afghanistan, Algeria, Brazil, Iran, and Syria.5 Throughout
the world, 1e1.5 million new cases of the disease are reported
annually.3 Different drugs such as miltefosin, liposomaly and Entomology, Faculty of
ad St., Tehran, Iran.
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molecules, National Taiwan Univeamphotericin B, paromomycin, and allopurinol have been used to
treat this disease,6 but the ﬁrst-line drug treatment for CL is anti-
mony compounds. Two popular types are sodium stibogluconate or
pentostam and meglumine antimoniate; however, these com-
pounds have adverse effects, and drug resistance and relapse after
treatment can occur.5,7,8 Factors associated with unsuccessful
treatment include the presence of more than three cutaneous le-
sions, previous treatment, body weight above 68 kg, and an
incomplete treatment schedule.9 Aloe-emodin (1,8-dihydroxy-3-
hydroxymethyl-anthraquinone; Fig. 1), an exudate from the aloe
plant,10 is an anthraquinone in aloe vera and other species of the
Asphodelaceae and Polygonaceae families. Some studies have
indicated that aloe-emodin has antibacterial, antifungal, antiviral,
diuretic, immunosuppressive, hepatoprotective, laxative, anti-
inﬂammatory, and anticancer speciﬁcities.11e14 Aloe-emodin
reportedly inhibits the replication of enveloped viruses such as
herpes simplex virus, inﬂuenza virus, and human cytomegalo-
virus.15 Aloe-emodin induces apoptosis through the release of
apoptosis-inducing factors and cytochrome c from the mitochon-
dria in human gastric carcinoma cells.16 This compound has arsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Chemical structure of aloe-emodin.
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which is exerted by inducing cell differentiation.17 It also has
anticancer activity against human promyelocytic leukemia cells18
and human hepatoma cells.19 The aim of the present study was to
evaluate antileishmanial activity of aloe-emodin under in vitro and
in vivo conditions.
2. Materials and methods
2.1. Preparation of aloe-emodin
Aloe-emodin powder was purchased from the Selleckchem
Company (Houston, TX, USA) and dissolved in dimethyl sulfoxide
(DMSO) at the concentration of 20 mg/mL. For the in vitro study,
four concentrations were prepared: 40 mg/mL, 80 mg/mL, 120 mg/
mL, and 160 mg/mL. Two concentrations (10 mg/mL and 1 mg/mL)
were also prepared for the in vivo assay in an ointment base by
Eucerin.
2.2. Leishmania culture
L. major (MRHO/IR/75/ER) promastigotes were cultivated in
Roswell Park Memorial Institute (RPMI) 1640 medium, which
contained penicillin (100 units/mL), streptomycin (100 mg/mL), and
20% fetal bovine serum, in an incubator 24 ± 2C. The stationary
phase of parasites was obtained by culture promastigotes in
NovyeMacNealeNicolle medium.
2.3. Antiamastigotes assay
The drug susceptibility of amastigotes in BALB/c mouse mac-
rophages was determined using the modiﬁed method by Love
et al.20 In brief, peritoneal macrophages were isolated from the
peritoneum of BALB/c mice. They were added onto a glass coverslip
in tissue culture on 12-well plates and incubated for 24 hours at
37C with 5% carbon dioxide. Nonadherent macrophages were
removed by washing. Adherent macrophages were adjacent to the
stationary growth phase of promastigotes at a parasite/macrophage
ratio of 10:1. After 24 hours of incubation under the previous
condition, washing was repeated and different concentrations (i.e.,
40 mg/mL, 80 mg/mL, 120 mg/mL, and 160 mg/mL) of aloe-emodin
were added to the infected macrophages in the wells and incu-
bated separately for 24 hours and 48 hours. The coverslips were
stained with Giemsa stain and the number of amastigotes inside
the macrophages were counted (100 macrophages per coverslip).
2.4. Flow cytometry analysis
The promastigotes were cultured in 24-well plates (3  105
parasites per well) in the absence of aloe-emodin (i.e., negative
control group) and in the presence of 40 mg/mL and 120 mg/mL of
aloe-emodin. They were incubated at 24C. The Annexin V FLUOS
Staining Kit (Biovision, USA) was used to detect apoptotic and
necrotic cells. In accordance with the kit instructions, the pro-
mastigotes were collected after a 24-hour incubation and a 48-hourincubation. They were centrifuged at 3000 rpm for 5 minutes. The
supernatant was then discharged, and 500 mL binding buffer, 5 mL
Annexin V, and 5 mL propidium iodide were added to the residue.
The samples were incubated at room temperature and under a dark
condition for 5 minutes. They were then obtained by BD FACSCanto
II ﬂow cytometer (BD Biosciences, San Jose, CA) and were analyzed
by FlowJo Software (BD Biosciences).
2.5. In vivo assay
An ointment was prepared with 10 mg/mL (1%) and 1 mg/mL
(0.1%) aloe-emodin in a standard ointment base (Eucerin). Forty
female BALB/c mice that were 6e7 weeks old were used in this
study. All mice were inoculated subcutaneously in a shaved area
above the tail with approximately 2  106 stationary stages of
Iranian strains of L. major promastigotes. Forty mice were divided
into four groups with each group containing 10 mice. The groups
were classiﬁed as follows: Group 1 was treated with the 1% aloe-
emodin ointment; Group 2 was treated with the 0.1% aloe-
emodin ointment; Group 3 was treated with only the ointment
base (i.e., Eucerin); and Group 4 was untreated (i.e., control group).
Treatment was initiated when local lesions were obvious. The mice
were treated topically twice daily for 30 continuous days. Each
week, the lesion size was measured before and after treatment by
vernier calipers in two diameters (a, b). The lesion size was calcu-
lated by the formula:
Lesion size ðLSÞ ¼ ðaþ bÞ=2: (1)
2.6. Biochemical analysis
To evaluate the toxic effects of aloe-emodin in the livers and
kidneys of the mice, serum samples were collected from a group of
12 mice. Aspartate aminotransferase, alanine aminotransferase,
alkaline phosphatase, creatinine, urea, sodium and potassiumwere
measured using Pars azmoon kit (Iran) and Hitachi Analyzer
(Japan).
2.7. Statistical analysis
Statistical signiﬁcance between groups was analyzed by one-
way analysis of variance (ANOVA) using SPSS version 16 software
(SPSS Inc., Chicago, IL, USA) and the obtained p < 0.05 were
considered signiﬁcant.
3. Results
3.1. Antiamastigote effect
After adding 160 mg/mL aloe-emodin, the mean number of
amastigotes/macrophage after 24 hours and 48 hours was 1.3 and
0.9, respectively, and in the negative control group the mean
number was 4.3 and 4.8, respectively. Fig. 2 shows the other con-
centration results.
3.2. Flow cytometry analysis
The treatment of promastigotes at two concentrations of aloe-
emodin (i.e., 40 mg/mL and 120 mg/mL) for 24 hours and 48 hours
resulted in necrotic and apoptotic effects in the parasite. The
percent of apoptosis in promastigotes induced by 40 mg/mL and
120 mg/mL of aloe-emodin after 24 hours was 13.45% and 68.3%,
respectively; after 48 hours, it was 15.43% and 70.2%, respectively
(Fig. 3).
Table 1
Themean lesion size in the test and control groups after treating themice with aloe-
emodin for 4 weeks.
Group Concentration
(mg/mL)
Lesion size (mm)
before treatment
Lesion size (mm)
after treatment
Mean ± SD Mean ± SD
1 1 6.1 ± 0.9 5.4 ± 0.6*
2 10 5.8 ± 1.1 2.1 ± 1.9*
3 0 6.1 ± 0.8 13.8 ± 1.6
4 0 5.23 ± 1.3 14.1 ± 1.3
* Indicates a signiﬁcant difference with Groups 3 and 4 (p < 0.05).
Table 2
Serum biochemical analysis of mice treated with aloe-emodin for 4 weeks.
Biochemical Factors Aloe-emodin 0.1% Aloe-emodin 1% Control
ALT (IU/L) 57 ± 1.5 60 ± 1.7 56.2 ± 2.2*
AST (IU/L) 84 ± 2.9 86 ± 4.2 87.1 ± 4.1*
ALKP (IU/L) 101 ± 6.3 98.7 ± 4.7 97 ± 8.1*
Cr (mg/dL) 0.36 ± 0.21 0.38 ± 0.3 0.37 ± 0.32*
Urea (mg/dL) 31 ± 1.1 30 ± 3.5 27.1 ± 2.4*
Na (mg/dL) 166 ± 4.3 167 ± 6.8 165 ± 5.3*
K (mg/dL) 5.5 ± 0.9 6 ± 1.1 6.1 ± 0.8*
ALT¼ alanine aminotransferase; AST¼ aspartate aminotransferase; Cr¼ creatinine;
K ¼ potassium; Na ¼ sodium.
* No signiﬁcant differences were observed between control and treated groups
(p > 0.05).
Fig. 2. The mean number of amastigotes/macrophages at 24 hours and 48 hours after
treatment with different concentrations of aloe-emodin.
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The mean LS decreased in the groups treated with aloe-emodin,
compared to the control groups. The mean LS in the untreated
groups was 14.1 mm, whereas it was 5.4 mm and 2.1 mm in groups
treated with the 1 mg/mL and 10 mg/mL concentration of aloe-
emodin, respectively. There was no signiﬁcant difference in the
mean LS between Groups 3 and 4, whereas the mean difference
between Groups 1 and 2 versus the control groups was signiﬁcant
(p < 0.05; Table 1).
3.4. Biochemical analysis
No signiﬁcant differences were observed between the control
groups and the treated groups (p > 0.05; Table 2). This result
showed that the cutaneous application of aloe-emodin has no
adverse effects on liver and kidney factors.
4. Discussion
Drug resistance and the adverse effects of common drugs used
in the treatment of CL and relapses in improved patients increases
the need for pharmacological studies to achieve effective and safe
drugs. The enhanced anti microorganism capability of aloe vera is
attributed to aloe-emodin, which has antibacterial, antifungal, and
anticancer effects.12e14 The results of our work showed that aloe-
emodin reduces the number of L. major amastigotes inFig. 3. Flow cytometry result. Promastigotes were stained with Annexinmacrophages. A comparison of the amastigotes number in the
control and test groups at two different times showed that the ef-
ﬁcacy of aloe-emodin is dose- and time-dependent, and that aloe-
emodin reduces the number of parasites with increasing concen-
tration of aloe-emodin. Results showed aloe-emodin induces
apoptosis in Lesihmania major promastigotes in a dose- and time-
dependent manner so that the rate of apoptosis increased with
increasing aloe-emodin concentration and time.
Aloe-emodin induces apoptosis in human gastric carcinoma
cells and glioma cells.16,21 Aloe vera leaf exudate induces a caspase-
independent cell death in Leishmania donovani promastigotes.22
The mechanism of apoptosis induced in L. major promastigotes by
aloe-emodin is unclear. Topical application of aloe-emodin showed
that using this compound on a CL wound reduces the size of the
lesion. The mean LS reduced to 2.1 mm after using 1% aloe-emodin
ointment. This difference was statistically signiﬁcant with the
control group (14.1 mm). The number of amastigotes in macro-
phage was reduced under the in vitro condition. The in vivo study
showed that aloe-emodin has a favorable effect on wound healing;V and propidium iodide 48 hours after treatment with aloe-emodin.
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studies, aloe-emodin has many effects on different microorganisms
such as viruses, fungi, and bacteria, and it reportedly exhibits
anticancer activity on neuroectodermal tumors, lung squamous cell
carcinomas, and hepatoma cells.16 No study has been performed
using aloe-emodin on CL; however, useful studies that have eval-
uated the therapeutic effects of aloe vera on cutaneous and visceral
leishmaniasis show that aloe vera has antileishmanial activity by
activation of host macrophages and that it reduces parasitemia by
>90% in the liver, spleen, and bone marrow.23,24 Selecting effective
compounds with no potential toxicity has an important role in
introducing new treatments for CL. With regard to the aforemen-
tioned issue, the serum biochemical factors were analyzed. The
results indicated no signiﬁcant differences between the test and
control groups, and aloe-emodin has no adverse effects on liver and
renal factors. However, more biochemical analysis and pathological
investigation are needed to survey the adverse effects of aloe-
emodin. It may be that using aloe-emodin with other skin repair
compounds considerably contributes to wound healing.
5. Conclusion
In general, the results of this study demonstrated for the ﬁrst
time that aloe-emodin exhibits antileishmanial activity under
in vitro and in vivo conditions. Different concentrations of aloe-
emodin and various using methods are required before any
conclusion can be formed about the efﬁcacy of aloe-emodin in the
treatment and healing of human CL wounds.
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